Stand Up to Cancer is teaming with Microsoft and SITC to provide a new round of $11 million in grants to study cancer immunotherapies.
Female grant applicants do about as well as their male colleagues when the review focuses on the science proposed, according to Nature News.
Over the next three years, the company and its partners will assess the OneRNA platform to diagnose bladder cancer, select treatment, and measure response and recurrence.
The new European initiative promises to deliver multiple new tests and methods for improving the treatment of breast cancer and rectal cancer.
The companies will use Sphere's Cyto-Mine system to develop an automated device for precise docking of large DNA cargoes in genome-edited cells.
Backed by €19 million in EU funding, the initiative, called BigData@Heart, will create a research platform that could change the way cardiovascular diseases are diagnosed and treated.
The firm plans to develop and evaluate the utility of an ethnically diverse group of metastatic prostate cancer patient-derived xenograft models.
Doudna will get $2.1 million to set up the Center for Genome Editing and Recording, and Zhang will get $1.1 million to develop tools for RNA interrogation.
The UK-based company plans to use the funds to develop an automated, benchtop device for the creation of high-value, genome-edited cell lines.
NASA's Jet Propulsion Laboratory is providing informatics services for an NCI-funded project to standardize cancer genomics ontologies.
The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.
US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.
Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.
In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.